TakeAim
TakeAim Leukemia: A Phase 1/2A, Open Label Dose Escalation and Expansion Study of Orally Administered CA-4948 as a Monotherapy in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome and in Combination With Azacitidine or Venetoclax
Arms / Cohorts
Experimental:Dose Escalation: Emavusertib (CA-4948)
Accepting patients
Experimental:Dose Escalation: Emavusertib + Azacitidine
Accepting patients
Experimental:Dose Escalation: Emavusertib + Venetoclax
Accepting patients
Experimental:Dose Expansion: Emavusertib
Accepting patients
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.